Patents by Inventor Clark M. Whitehead
Clark M. Whitehead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200150008Abstract: An efficient manual method for preparing a cytology sample for staining. According to the method, a biological sample is provided, wherein the biological sample is a liquid-based cytology sample. A slide is placed in a holder adapted for receiving the slide. The slide is pre-coated with a composition that will cause cells to adhere to the slide. A settling chamber is placed over said slide and the settling chamber is locked onto the holder. The settling chamber has openings in both proximate and distal ends. The opening in the distal end of the settling chamber is positioned over the slide such that the slide is interposed between the holder and the settling chamber and the slide is in fluid communication with the settling chamber. A density reagent is then dispensed into the settling chamber. The liquid-based cytology sample is then dispensed into the settling chamber over the reagent. The assembly formed by the holder, slide and settling chamber (and its liquid contents) is placed in a centrifuge.Type: ApplicationFiled: July 18, 2018Publication date: May 14, 2020Applicant: BECTON DICKINSON AND COMPANYInventors: Ryan Callaghan, Clark M. Whitehead, William Alan Fox
-
Patent number: 10527526Abstract: Compositions and methods for preparing a sample for immunological staining are provided. Compositions include kits comprising a first solution comprising a surfactant and a second solution comprising a chaotropic agent. Methods comprise contacting a sample, such as cells or tissues, with a first solution comprising a surfactant and then contacting the sample with a second solution comprising a chaotropic agent. The method does not require extreme heat for antigen retrieval and therefore, maintains the cellular morphology of the sample.Type: GrantFiled: November 2, 2012Date of Patent: January 7, 2020Assignee: Tripath Imaging, Inc.Inventors: Timothy J. Fischer, Ramona R. Nelson, Adriann J. Taylor, Clark M. Whitehead
-
Patent number: 8476033Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention.Type: GrantFiled: July 27, 2012Date of Patent: July 2, 2013Assignee: TriPath Imaging, Inc.Inventors: Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20130022998Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention.Type: ApplicationFiled: July 27, 2012Publication date: January 24, 2013Applicant: TriPath Imaging, Inc.Inventors: Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Patent number: 8252904Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided.Type: GrantFiled: March 5, 2010Date of Patent: August 28, 2012Assignee: Tripath Imaging, Inc.Inventors: Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20100227343Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Becton, Dickinson and CompanyInventors: Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20100227335Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Becton, Dickinson and CompanyInventors: Jeffrey P. Baker, Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20090269856Abstract: Methods and compositions for evaluating the prognosis of a breast cancer patient, particularly an early-stage breast cancer patient, are provided. The methods of the invention comprise detecting expression of at least one, more particularly at least two, biomarker(s) in a body sample, wherein overexpression of the biomarker or a combination of biomarkers is indicative of breast cancer prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The biomarkers of the invention are proteins and/or genes whose overexpression is indicative of either a good or bad cancer prognosis. Biomarkers of interest include proteins and genes involved in cell cycle regulation, DNA replication, transcription, signal transduction, cell proliferation, invasion, proteolysis, or metastasis.Type: ApplicationFiled: May 14, 2009Publication date: October 29, 2009Applicant: TriPath Imaging, IncInventors: Timothy J. Fischer, Clark M. Whitehead, Douglas P. Malinowski, Raphael Marcelpoil, Didier Morel
-
Publication number: 20090075307Abstract: Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided.Type: ApplicationFiled: October 30, 2008Publication date: March 19, 2009Applicant: TriPath Imaging, Inc.Inventors: Timothy J. Fischer, Douglas P. Malinowski, Qin He, Clark M. Whitehead, Robert L. Cheek, John W. Groelke
-
Publication number: 20090068690Abstract: Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided.Type: ApplicationFiled: October 30, 2008Publication date: March 12, 2009Applicant: TriPath Imaging, Inc.Inventors: Timothy J. Fischer, Douglas P. Malinowski, Qin He, Clark M. Whitehead, Robert L. Cheek, John W. Groelke
-
Publication number: 20030176316Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of rheumatoid arthritis.Type: ApplicationFiled: October 23, 2002Publication date: September 18, 2003Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
-
Publication number: 20030073711Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of scleroderma.Type: ApplicationFiled: August 23, 2001Publication date: April 17, 2003Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
-
Publication number: 20030073741Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of multiple sclerosis.Type: ApplicationFiled: May 21, 2002Publication date: April 17, 2003Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
-
Publication number: 20030073740Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of lupus erythematosus.Type: ApplicationFiled: August 23, 2001Publication date: April 17, 2003Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
-
Patent number: 6479493Abstract: Substituted condensation products of -benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of type I diabetes.Type: GrantFiled: August 23, 2001Date of Patent: November 12, 2002Assignee: Cell Pathways, Inc.Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
-
Patent number: 6465494Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of cystic fibrosis.Type: GrantFiled: August 24, 2001Date of Patent: October 15, 2002Assignee: Cell Pathways, Inc.Inventors: Keith A. Earle, Hector W. Alila, Clark M. Whitehead, W. Joseph Thompson